The tweet was deleted by the author.
But we saved everything 🙂.
Definium Therapeutics hosted its Investor and Analyst Day in New York City, sustaining recent optimism for psychedelic treatment options.
The event brought together the company’s executive leadership and leading clinicians to discuss strategic advancements and ongoing developments in the psychedelic therapies sector. This gathering follows a series of recent company updates positioning Definium Therapeutics at the forefront of innovative mental health solutions. Investors and analysts were briefed on the latest clinical initiatives, underlining the company’s commitment to new breakthroughs in the field.
Definium Therapeutics previously scheduled its Investor and Analyst Day in New York City for April 22. The company had outlined plans to present insights into the psychedelic treatment landscape at the event. This follows continued efforts to engage investors with updates on its clinical strategy.